The combined challenges of poor tissue accumulation and rapid clearance of agents by the liver and kidney require larger doses of agents. Increased doses lead to toxicity and inflammatory or immune responses. Collectively, these challenges limit the therapeutic window between a therapy that is efficacious and one that is toxic, increase the costs to patients, and very often limit the places in the body where effective therapies can be developed.

What is Brushield™? It is an oligonucleotide enhancer technology that will allow pacDNA to significantly accelerate lead-to-IND stage drug development for our clients and partners. The technology mitigates toxicities and almost all other side effects stemming from unwanted nucleic acid-protein interactions, while making the active component more efficacious. The Brushield™ technology is highly differentiated and can yield drug candidates with far superior biopharmaceutical properties including reduced side effects, non-immunogencity, enhanced pharmacokinetics, and non-liver/kidney biodistribution. Our research has generated substantial data pointing to Brushield™ being a highly translatable approach for realizing non-hepatic gene regulation, which remains a key challenge in the development of viable therapeutics.